The promise of
IGC-AD1
Findings from phase 1 study suggest that IGC-AD1 has the potential to safely reduce the debilitating symptoms affecting millions of Alzheimer’s patients.
Phase 1 and Phase 2 trials are registered on clinicaltrials.gov
IGC-AD1 Timeline
2017
IGC Pharma begins development of the IGC-AD1 oral formulation.
2019
IGC-AD1 is approved by the FDA as an investigational new drug.
2021
Phase 1 clinical trial testing safety and tolerability in humans with Alzheimer’s successfully completed.
IGC-AD1 is awarded patent protection in the U.S.
2022
Phase 2 clinical trial to evaluate the efficacy of IGC-AD1 begins.
Additional patent awarded protecting IGC-AD1 formulation.
2023
IGC-AD1 is awarded patent protection in México.
Pre-clinical
Preclinical studies have allowed us to identify the potential of IGC-AD1 to be an AD-modifying drug. The combination of the active ingredients at low, non-toxic concentrations was shown to reduce Aβ aggregation in N2aAβPPswe cells, maintain APP levels, and enhance mitochondrial function in a dose-dependent manner.
Phase I Clinical Trail
Overall Study Design:
Participants with mild to severe Alzheimer’s disease
Participants were sequentially administered three doses over 14 days: once a day (QD), twice a day (BID), and three times a day (TID)
Double-blind
Phase II Clinical Trail
brings hope
As millions of Alzheimer’s patients presents agitation, our ongoing Phase 2 trial brings hope for a treatment.
Clinical trial includes up to 20 sites in the U.S. and Canada with a target of 146 participants.
Why IGC-AD1 & Alzheimer’s?
IGC-AD1 includes two Active Pharmaceutical Ingredients (APIs)
The APIs in IGC-AD1 have been shown to reduce the plaque build-up associated with Alzheimer’s in cell lines.
The API have been shown to promote mitochondrial functioning in pre-clinical studies
The API have been shown to restore spatial memory in a mouse model of Alzheimer’s.
As an oral liquid solution, IGC-AD1 could be an effective, simpler treatment option for patients
